Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Boehringer Ingelheim today announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between six and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).
Childhood ILD (chILD) includes more than 200 rare respiratory disorders that can affect infants, children and adolescents, making it difficult for them to breathe. In some cases, fibrosis which involves scarring and damage to the lungs can develop. This can lead to a significant impact on the daily life of those affected, as well as their families, including high morbidity and mortality. There are currently no approved therapies available for the treatment of chILD.
“Some children with interstitial lung disease may develop serious fibrosis that progresses,” said the coordinating investigator Prof. Robin Deterding, M.D., Director of the Breathing Institute, Children's Hospital Colorado. “Though the underlying causes of pulmonary fibrosis may be different in children, we’re excited to determine if treating the mechanism of fibrosis improves children’s lung fibrosis as it does in adults.”
Nintedanib, which is marketed as Ofev®, is currently approved in more than 80 countries for the treatment of people living with idiopathic pulmonary fibrosis (IPF).4 It is also approved in more than 40 countries as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD (SSc-ILD).5 Ofev® recently also obtained approval in the USA, Canada, Japan, Brazil, Argentina and the EU, for a third indication, as the first and only treatment for patients living with chronic fibrosing ILDs with a progressive phenotype.2,3
“Boehringer Ingelheim is proud to start this trial to provide valuable insights as we evaluate this potential treatment for children and adolescents with these rare and heterogenous conditions for which there are currently no treatments with proven efficacy and no randomized controlled trials,” said Dr Susanne Stowasser, Associate Head of Medicine Pulmonology at Boehringer Ingelheim. “This study represents our ongoing commitment to address unmet needs and advance research for adult and pediatric patients living with pulmonary fibrosis.”
For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/inpedildtrialenrollment
Media + PR
Dr Ralph Warsinsky.
Phone +49 6132 77 7051
Mobile +49 178 290 8561
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EURid-Coordinated Dynamic Coalition on Data and Trust Officially Launched24.9.2020 14:00:00 EEST | Press release
EURid today announces the launch of a new Dynamic Coalition on Data and Trust (DC-DT) for the 2020 Internet Governance Forum. In recent years, disinformation scandals and increasing levels of consolidation in technology markets have diminished the confidence of regulators and members of the public in the effectiveness of industry self-regulation. The Dynamic Coalition will deepen understanding of these issues and build consensus among interested stakeholders. The new group is a partnership with multiple stakeholders across the private, public and civil society sectors including European Commission, Europol and the Computational Propaganda Unit at Oxford University’s Internet Institute and members of the International Trade Mark Association. The key aims and activities of the Coalition will include: 1. Exploring linkages between data and trust to inform policy discussions with a solid evidence base and showcase relevant research which explores linkages between data, information and trus
Best Buy, McKinstry, Real Betis, Schneider Electric, and Siemens Sign The Climate Pledge24.9.2020 13:00:00 EEST | Press release
Today, Amazon (NASDAQ: AMZN) and Global Optimism announced that Best Buy, McKinstry, Real Betis, Schneider Electric, and Siemens have joined The Climate Pledge , a commitment to be net-zero carbon by 2040—a decade ahead of the Paris Accord’s goal of 2050. These new signatories to The Climate Pledge agree to: Measure and report greenhouse gas emissions on a regular basis; Implement decarbonization strategies in line with the Paris Agreement through real business changes and innovations, including efficiency improvements, renewable energy, materials reductions, and other carbon emission elimination strategies; Neutralize any remaining emissions with additional, quantifiable, real, permanent, and socially-beneficial offsets to achieve net-zero annual carbon emissions by 2040. “From hurricanes to forest fires, climate change is leading to very real, negative impacts to our daily lives even sooner than scientists expected. Every company has a role to play in fighting climate change, and we
Universal Peace Federation (UPF) Holds 2nd Online “Rally of Hope”24.9.2020 12:57:00 EEST | Press release
The Universal Peace Federation (UPF) is announcing that a second global Rally of Hope will be held this weekend, featuring world leaders who see new opportunities for peacebuilding in all sectors of society. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005400/en/ Universal Peace Federation (UPF) holds 2nd Online “Rally of Hope”. Global leaders come together for peace based on ideals of interdependence, mutual prosperity and universal values. (Photo: Business Wire) Dr. Hak Ja Han Moon, co-Founder of the Universal Peace Federation, will be the keynote speaker. Other luminaries include Sao Tome and Principe President Evaristo Carvalho; U.S. Vice President Dan Quayle (1989-1993); former European Commission Chairman Jose Manuel Barroso (2004-2014); Nigeria President Goodluck Jonathan (2010-2015); Evangelical Lutheran Church Bishop (Emeritus) Munib Younan; and Roman Catholic Archbishop (Emeritus) of Castries Kelvin Edward
NanoTemper Technologies Launches DLS Capability With Prometheus Panta, Bringing High-Resolution, Domain-Specific Stability Characterization to Biologics24.9.2020 12:48:00 EEST | Press release
NanoTemper Technologies, well-known for creating tools that address challenging characterizations, today introduced Prometheus Panta, a multi-parameter stability characterization instrument. By combining DLS for particle size determination with nanoDSF for thermal unfolding and backreflection for aggregation, researchers in biologics formulation optimization, developability, or comparability assessments will find that Prometheus Panta offers superior characterization of their candidate molecules. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005395/en/ (Photo: Business Wire) “Inevitably, researchers will come across candidate molecules that present challenges. Here’s where Prometheus Panta shines, offering a solution they can rely on for clear, trustworthy, and high-resolution data for colloidal and conformational stability,” said Philipp Baaske, Co-CEO of NanoTemper. Having the right technology really matters when re
Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators24.9.2020 12:25:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA open-label extension study, which showed safety and efficacy consistent with the results of the Phase 3 pivotal studies in patients with CF ages 12 and older with F508del/Minimal Function (F/MF) or F508del/F508del (F/F) genotypes. Four additional scientific abstracts for ORKAMBI® and TRIKAFTA® were published in the Journal of Cystic Fibrosis as part of the ECFS conference. In addition, six scientific presentations will occur at NACFC regarding KALYDECO,® ORKAMBI and TRIKAFTA, including new data from KALYDECO in infants a
Ant Group’s INCLUSION Fintech Conference Debuts in Shanghai24.9.2020 12:00:00 EEST | Press release
Ant Group, an innovative technology provider, today officially launched its inaugural INCLUSION Fintech Conference, welcoming prominent speakers from all corners of the world, including representatives from the United Nations and the International Monetary Fund, as well as Nobel Prize-winning scholars, to participate in a wide-ranging conversation on how digital technology can help build a more inclusive, green, and sustainable world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005369/en/ IMF Managing Director Kristalina Georgieva delivers keynote speech at inaugural INCLUSION Fintech Conference (Photo: Business Wire) Taking place both online and onsite in Shanghai from September 24-26, 2020, the conference brings together thought leaders from across the globe to envision the digital economy of the future. The first day of the conference began with a morning plenary session, followed by 17 forums in the afternoon an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom